Optimized Basement Membrane Extracts for Organoid Growth and Xenograft Models
AMSBIO announces the availability of two new formulations of Basement Membrane Extract (BME) known as Cultrex BME 2 (organoid growth matrix) and Cultrex BME 3 (xenograft/tumorgraft matrix).
The new products have been developed to address the heterogeneous nature of tissue and organ micro-environments that not only arise from organ specific stromal cells, growth factors, proteoglycans, and protein composition but also from the stiffness or tensile strength of the BME. Many studies have shown that there is a relationship between abnormal tensile strength and both cancer progression and fibrotic tissues. It is both the chemical and physical properties of the BME that are responsible for the mechanical and biological properties of tissues and organs. It was in light of this heterogeneity that Cultrex BME 2 and Cultrex BME 3 were developed.
BME 2 is based upon a proprietary formulation that is higher in tensile strength than original Matrigel or Cultrex BME. This growth factor reduced product is recommended for organoid growth applications including 3D cell culture from stem cells. By comparison, BME 3 has been developed to be physiologically aligned with the in vivo tumour environment and is recommended for xenografts, tumorgrafts and other in vivo applications.
Basement membranes are continuous sheets of specialized extracellular matrix that form an interface between endothelial, epithelial, muscle, or neuronal cells and their adjacent stroma. Basement membranes are degraded and regenerated during development and wound repair. They not only support cells and cell layers, but they also play an essential role in tissue organization that affects cell adhesion, migration, proliferation, and differentiation. Basement membranes provide major barriers to invasion by metastatic tumour cells. Cultrex BME is a soluble form of basement membrane purified from Engelbreth-Holm-Swarm (EHS) tumours. The extract gels at 37 °C to form a reconstituted basement membrane. The major components of BME include laminin, collagen IV, entactin, and heparin sulphate proteoglycan. BME can be used for growth promotion or for the differentiation of precursor cells, under a variety of cell culture conditions, involving primary epithelial, endothelial and smooth muscle cells. BME has also been employed in cell attachment, neurite outgrowth, angiogenesis assays, in vitro cell invasion and in vivo tumorigenicity assays.
For further information on Cultrex BME 2 and Cultrex BME 3 please visit http://www.amsbio.com/
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance